0.82
-8.89%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eagle Pharmaceuticals
Its shares trade under the ticker EGRX. It has been listed since 12 February 2014. In the fiscal year to 31 December 2022, it reported revenue of $316.6m and net income of $35.6m. At that date it held total assets of $406.2m and shareholders' equity of $233.6m.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. The company is headquartered in Woodcliff Lake, New Jersey. The company went IPO on 2014-02-12. The firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The firm's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Feb 2014
- Employees
- 106
- Website
- eagleus.com ↗
Leadership
Pay as last reported
- Mr. Michael GravesInterim Executive Chairman of the Board, Interim Principal Executive Officer, since 2013$391,026
- Mr. Christopher KrawtschukChief Financial Officer, Principal Financial Officer and Principal Accounting Officer
- Mr. Steven RatoffDirector, since 2007$331,026
- Dr. Luciana BorioIndependent Director$308,526
- Mr. Richard EdlinIndependent Director$312,276
- Mr. Robert GlenningIndependent Director$324,776
- Dr. Jennifer SimpsonIndependent Director$308,526
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 18
- Environment
- 3
- Social
- 22
- Governance
- 30
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eagle Pharmaceuticals Inc possesses several strengths that contribute to its success in the market:
- Eagle Pharmaceuticals Inc has established a robust market position in the pharmaceutical industry. This position enables the company to leverage its brand reputation and attract a loyal customer base.
- The company's product portfolio is characterized by its innovative and differentiated offerings. Eagle Pharmaceuticals Inc invests in research and development to continuously develop new drugs and drug delivery systems with superior therapeutic benefits.
- Eagle Pharmaceuticals Inc has formed strategic partnerships with key stakeholders in the healthcare sector. These collaborations allow the company to expand its reach, gain access to new markets, and capitalize on mutual strengths.
Weaknesses
- Despite its strengths, Eagle Pharmaceuticals Inc also faces some weaknesses that could hinder its growth:
- The company heavily relies on a few key products for its revenue generation. This lack of diversification makes Eagle Pharmaceuticals Inc vulnerable to changes in market demand or regulatory restrictions on specific drugs.
- Eagle Pharmaceuticals Inc relies on external contract manufacturers for the production of its drugs. This reliance introduces a level of dependency on third-party suppliers, potentially exposing the company to supply chain disruptions or quality control issues.
- The company's operations are primarily focused on the domestic market, limiting its exposure to international markets. This narrow geographic footprint means Eagle Pharmaceuticals Inc may miss out on significant growth opportunities in global healthcare markets.
Opportunities
- There are several potential opportunities that Eagle Pharmaceuticals Inc can explore to drive future growth:
- Entering emerging markets presents an opportunity for Eagle Pharmaceuticals Inc to capture untapped customer segments and increase its revenue. These markets often have growing healthcare needs and less competition.
- Investing in research and development to develop new drug formulations can provide Eagle Pharmaceuticals Inc with a competitive edge. Introduction of innovative products can attract more customers and generate additional revenue streams.
- Seeking strategic acquisitions or partnerships can help Eagle Pharmaceuticals Inc expand its product portfolio, gain market share, and access new technologies. Collaborating with established players in different therapeutic areas can enhance the company's overall offerings.
Threats
- Eagle Pharmaceuticals Inc should be mindful of potential threats that could impact its business:
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Intense competition can erode pricing power, increase marketing costs, and potentially impact profitability for Eagle Pharmaceuticals Inc.
- Stringent regulations and an evolving regulatory landscape can pose challenges for Eagle Pharmaceuticals Inc. Compliance with various regulatory requirements, including drug approvals, safety standards, and patent protection, is crucial to the company's operations.
- Price erosion in the pharmaceutical industry, driven by factors such as generic competition and cost containment efforts by payers, can negatively impact the profitability of Eagle Pharmaceuticals Inc. Additionally, reimbursement pressures from healthcare payers may restrict access to certain drugs or limit pricing flexibility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.